Gali Soria1, Ilana Hass2, Neora Yaal-Hahoshen3, Leonor Leider-Trejo4, Esther Shabtai5, Adit Ben-Baruch1

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Metastases in Neuroblastoma Factor-1, in the Development of Bone Marrow the CXC Chemokine Stromal Cell-Derived A Possible Role for CXCR4 and Its Ligand, Ben-Baruch Meshel,

Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?

BACKGROUND Over 75% of postmenopausal patients with metastatic breast cancer have hormone receptor-positive tumors. Endocrine therapy, with its more favorable toxicity profile than chemotherapy, is the preferred treatment modality for these patients. OBJECTIVES To assess our experience with fulvestrant, an antiestrogen, in an advanced phase of treatment, after progression on the classical ant...

Assessing the effectiveness of Dead Sea products as prophylactic agents for acute radiochemotherapy-induced skin and mucosal toxicity in patients with head and neck cancers: a phase 2 study.

BACKGROUND Mucositis and dermatitis are frequently encountered in patients treated with radiochemotherapy. Dead Sea products that contain minerals and other properties have proven effective in treating various skin diseases. OBJECTIVES To evaluate the effectiveness of Dead Sea products in reducing acute radiochemotherapy-induced side effects in patients with head and neck cancer. METHODS In...

Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer.

BACKGROUND The current methods for pre- and post-chemotherapy examination of the extent of disease in the breast and lymph nodes do not provide sufficiently accurate information and, not infrequently, the surgeon has to re-operate. OBJECTIVES To correlate the findings between three methods of examination (physical examination, ultrasonography, mammography), all performed by the same oncologic...